Skip to main content
    • Aa
    • Aa

Critical molecular abnormalities in high-grade serous carcinoma of the ovary

  • Martin Köbel (a1) (a2), David Huntsman (a1) and C. Blake Gilks (a1)

Ovarian carcinomas show more morphological heterogeneity than adenocarcinomas of any other body site. It has recently become clear that the morphologically defined subtypes of ovarian carcinoma are distinct diseases, with different risk factors, molecular events during oncogenesis, likelihood of spread, responses to chemotherapy, and outcomes. This review focuses on molecular abnormalities (in genes expressing BRCA1/2, TP53 and RB1/CCND1/CDKN2A/E2F) found in high-grade serous carcinomas of the ovary, which account for most ovarian cancer deaths. These highly aggressive but chemosensitive tumours are associated with perturbation of molecular pathways leading to genomic instability and extreme mutability and present unique challenges in oncological research and practice.

Corresponding author
*Corresponding author: C. Blake Gilks, Department of Pathology, Room 1207 1st floor JPPN, Vancouver General Hospital, 855 West 12th Ave, Vancouver, BC, Canada, V5Z 1M9. Tel.: +1 (604) 875 4901; Fax: +1 (604) 875 4797; E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2 N. Auersperg (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22, 255-288

3 C.P. Crum (2007) Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 5, 35-44

5 J.D. Seidman (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23, 41-44

7 M. Takano (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94, 1369-1374

8 A. duBois (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95, 1320-1329

10 I. Shih and R.J. Kurman (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164, 1511-1518

14 M. Al Hussaini (2004) WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44, 109-115

15 A. Malpica (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28, 496-504

16 A. Malpica (2007) Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31, 1168-1174

17 G. Singer (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95, 484-486

18 G. Singer (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29, 218-224

19 M.A. Crispens (2002) Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99, 3-10

20 D.M. Gershenson (2006) Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108, 361-368

22 C.B. Gilks (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 23, 200-205

23 F. Medeiros (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30, 230-236

24 D.W. Kindelberger (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 31, 161-169

27 A.N. Tutt (2005) Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 70, 139-148

28 A. Tutt (2001) Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 20, 4704-4716

29 B. Modan (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345, 235-240

30 R. Moslehi (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66, 1259-1272

31 H.A. Risch (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68, 700-710

32 J.L. Hilton (2002) Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 94, 1396-1406

33 J.Z. Press (2008) Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17

34 P.A. Shaw (2002) Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 21, 407-411

36 N. Collins (1997) Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer 76, 1150-1156

37 L.A. Brown (2006) Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100, 264-270

38 A. Raouf (2005) Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst 97, 1302-1306

39 J. Boyd (2000) Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 283, 2260-2265

40 Y. Ben David (2002) Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20, 463-466

41 J.E. Quinn (2007) BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. Clin Cancer Res 13, 7413-7420

42 A. Bhattacharyya (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275, 23899-23903

43 S.A. Narod and J. Boyd (2002) Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 14, 19-26

44 H. Farmer (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921

45 W. Sakai (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120

46 S.L. Edwards (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115

47 E.M. Swisher (2008) Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68, 2581-2586

48 B. Vogelstein and K.W. Kinzler (2004) Cancer genes and the pathways they control. Nat Med 10, 789-799

49 D. Xing and S. Orsulic (2006) A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 66, 8949-8953

51 R. Wu (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11, 321-333

52 A. Garcia (2000) Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation. Int J Gynecol Pathol 19, 152-157

53 R. Salani (2008) Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 18, 487-491

54 L. Havrilesky (2003) Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21, 3814-3825

55 C.S. Moreno (2007) Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas. PLoS ONE 2, e441

59 H. Lassus (2003) Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91, 504-512

62 T. Bonome (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65, 10602-10612

63 C.B. Gilks (2005) Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 96, 684-694

64 I. Meinhold-Heerlein (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24, 1053-1065

67 D. Katsaros (2004) Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 94, 685-692

68 J.E. Armes (2005) Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 24, 363-368

69 A. Bali (2004) Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10, 5168-5177

71 K.L. Gorringe (2007) High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 13, 4731-4739

72 S.L. Harris and A.J. Levine (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908

73 K. Nakayama (2007) Amplicon profiles in ovarian serous carcinomas. Int J Cancer 120, 2613-2617

74 A. Staebler (2006) Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 45, 905-917

75 S. Pelengaris (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2, 764-776

78 M.A. Bookman (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21, 283-290

79 E.K. Riener (2004) The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. Gynecol Oncol 95, 89-94

80 M. Tuefferd (2007) HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS ONE 2, e1138

81 D. Mayr (2006) HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 48, 149-156

82 C.H. Lee (2005) Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 24, 147-152

83 J.S. Berek (2003) Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 21, 168s-174s

84 L. Calzone (2008) A comprehensive modular map of molecular interactions in RB/E2F pathway. Mol Syst Biol 4, 173

85 H.K. Dressman (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25, 517-525

86 R. Agarwal and S.B. Kaye (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502-516

87 C.M. Perou (2000) Molecular portraits of human breast tumours. Nature 406, 747-752

88 A.A. Alizadeh (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511

91 D.A. Bell (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18 (Suppl. 2), S19-S32

92 C.P. Crum (2007) The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 19, 3-9

H. Naora (2007) The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev Mol Med 9, 1-12

C.A. Barton (2008) DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109, 129-139

D.S. Tan (2006) Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7, 925-934

Y.L. Hu (2003) Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 95, 733-740

C.A. Sherman-Baust (2003) Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377-386

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 3
Total number of PDF views: 33 *
Loading metrics...

Abstract views

Total abstract views: 234 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 22nd September 2017. This data will be updated every 24 hours.